Compare Infosys Limited (INFY) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Mesoblast Limited — how do they compare? Infosys Limited trades at $11.18 (market cap $46.65B), while Mesoblast Limited trades at $16.38 (market cap $2.17B). The key difference: Infosys Limited is far larger — about 21.5× Mesoblast Limited's market cap, and Infosys Limited pays a 4.63% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| INFY | MESO | |
|---|---|---|
Market Cap | $46.65B | $2.17B |
Sector | Technology | Technology |
52-Week High | $20.22 | $20.96 |
52-Week Low | $10.49 | $12.88 |
Enterprise Value | $43.87B | $2.17B |
Dividend Yield | 4.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $11.31, down 1.57% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with 16.44% net margins and 31.57% ROE, while recent earnings have mostly beaten expectations. Recent news highlights strategic AI collaborations with healthcare and financial services clients, positioning INFY as a leader in AI-driven business transformation.
The stock presents a valuation opportunity with a P/E of 14.14 below industry averages, supported by analyst consensus target of $12.28 (8.6% upside). However, bearish technical momentum and competitive pressures in IT services create near-term headwinds. The dividend yield of approximately 2.3% provides income support while investors await earnings catalysts.
MESO trades at $16.63, down 3.98% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $36 million for Ryoncil, showing strong commercial progress, but maintains a net income margin of -144.33% with significant losses. Recent news highlights pivotal Phase 3 trial milestones for chronic low back pain treatment and a $50 million non-dilutive financing draw.
Outlook is mixed: bullish analyst sentiment and clinical advancements offer upside potential, but high cash burn and persistent losses pose substantial risks. Investors should weigh the company's growth trajectory against its financial sustainability and regulatory milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
